Fig 1: Correlation of the reduction of the percentage of CD38+/CD8+T cells with the increase of anti-Tat IgA antibody titers, CD8+ T central memory and anti-Tat specific IL-2 production after Tat immunization.Multivariate regression model for repeated measures was applied to CD38+/CD8+ T cells (%), including as explicative factors anti-Tat antibody titers (IgM, IgG, IgA), CD8+ central memory (%) and anti-Tat IFN-γ, IL-2 and IL-4 cytokines, for immunized subjects (n = 70).
Fig 2: Cellular immune responses against Env or recall antigens after Tat immunization.Percentage of responders at baseline (blue bar) and up to week 48 (red bar) are stratified by Tat dose. Percentage of subjects showing (A) anti-Env production of IFN-γ, IL-2 and IL-4 (Tat 7.5 µg, n = 31; Tat 30 µg, n = 29) and (B) CD4+ or CD8+ lymphoproliferative responses (Tat 7.5 µg, n = 31; Tat 30 µg, n = 30); (C) anti-Candida cytokines production (Tat 7.5 µg, n = 32; Tat 30 µg, n = 29), and (D) CD4+ or CD8+ lymphoproliferative responses (Tat 7.5 µg, n = 31; Tat 30 µg, n = 29); (E) anti-CEF production of IFN-γ, IL-2 and IL-4 (Tat 7.5 µg, n = 34; Tat 30 µg, n = 32), and (F) CD4+ or CD8+ lymphoproliferative responses (Tat 7.5 µg, n = 31; Tat 30 µg, n = 29). The analysis was performed using the McNemar's test: *p<0.05, **p<0.01.
Fig 3: Anti-Tat cellular immune responses.(A) Percentage of subjects showing anti-Tat specific production of IFN-γ, IL-2 or IL-4, respectively, measured at baseline (blue bar) and up to week 48 after the first immunization (red bar) and stratified by Tat dose (Tat 7.5 µg, n = 35; Tat 30 µg, n = 33 subjects, respectively). (B) Percentage of subjects showing anti-Tat CD4+ or CD8+ lymphoproliferative responses measured at baseline and up to week 48 and stratified by Tat dose (Tat 7.5 µg, n = 31; Tat 30 µg, n = 31). The analysis was performed using the McNemar's test: *p<0.05, **p<0.01.
Supplier Page from R&D Systems, a Bio-Techne Brand for Human IL-2 ELISpot Kit